Quest PharmaTech Inc. (CVE:QPT – Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 2000 shares. The stock had previously closed at C$0.03.
Quest PharmaTech Stock Performance
The business has a 50-day moving average price of C$0.03 and a 200-day moving average price of C$0.03. The firm has a market capitalization of C$3.38 million, a price-to-earnings ratio of 0.67 and a beta of 0.00. The company has a quick ratio of 0.52, a current ratio of 0.40 and a debt-to-equity ratio of 4.35.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Further Reading
- Five stocks we like better than Quest PharmaTech
- Chipotle Mexican Grill Stock Rallies as Q2 Results Top Fears, Guidance Rises
- L3Harris’ Record Backlog Makes Its Stock Sell-Off Look Overdone
- Quantum Earnings Could Decide Whether the Sector’s Sell-Off Has Gone Too Far
- Microsoft Just Flipped the AI Spending Narrative Overnight
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
